2026 Gregory D. Cuny: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	62	10647	9827	4626	4155	185	16604

Overview

Gregory D. Cuny is affiliated with the University of Houston in the United States. Their research spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with particular focus on subfields such as Molecular Biology, Organic Chemistry, Epidemiology, Infectious Diseases, and Materials Chemistry.

The scientist's work covers several main topics, including:

Biochemical and Molecular Research
Cell death mechanisms and regulation
Cytomegalovirus and herpesvirus research
NF-κB Signaling Pathways
Parasitic Infections and Diagnostics
Amoebic Infections and Treatments
Traditional and Medicinal Uses of Annonaceae

Gregory D. Cuny has contributed to a range of recent publications. Notable papers include:

"RIPK protein kinase family: Atypical lives of typical kinases," 2020, Seminars in Cell and Developmental Biology
"Necroptosis blockade prevents lung injury in severe influenza," 2024, Nature
"Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge," 2021, npj Vaccines
"Targeted Degradation of the Oncogenic Phosphatase SHP2," 2021, Biochemistry
"Current status and challenges in drug discovery against the globally important zoonotic cryptosporidiosis," 2021, Animal Diseases

The frequent co-authors collaborating with Gregory D. Cuny are:

Anantha Lakshmi Duddupudi
Lizbeth Hedstrom
Alexei Degterev
Seungheon Lee
Shibin Chacko

Frequent venues where Gregory D. Cuny's research has been published include:

Bioorganic & Medicinal Chemistry Letters
ACS Infectious Diseases
The Cambridge Structural Database
European Journal of Medicinal Chemistry
The Journal of Organic Chemistry

Best Publications

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

Alexei Degterev;Zhihong Huang;Michael Boyce;Yaqiao Li

3526
Citations
Identification of RIP1 kinase as a specific cellular target of necrostatins.

Alexei Degterev;Junichi Hitomi;Megan Germscheid;Irene L Ch'en

2316
Citations
BMP type I receptor inhibition reduces heterotopic ossification

Paul B Yu;Donna Y Deng;Carol S Lai;Charles C Hong

729
Citations
Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.

Gregory D. Cuny;Paul B. Yu;Joydev K. Laha;Xuechao Xing

412
Citations
Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage

Xing Zeng;Frederic Sigoillot;Shantanu Gaur;Sungwoon Choi

343
Citations
Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line

Yichin Liu;Yichin Liu;Hilal A. Lashuel;Hilal A. Lashuel;Sungwoon Choi;Xuechao Xing

324
Citations
Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice

Zerong You;Sean I Savitz;Sean I Savitz;Jinsheng Yang;Alexei Degterev

306
Citations
Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model.

Daniel M. Rosenbaum;Alexei Degterev;Joel David;Pearl S. Rosenbaum

293
Citations
Structure-activity relationship study of novel necroptosis inhibitors.

Xin Teng;Alexei Degterev;Prakash Jagtap;Xuechao Xing

254
Citations
A new class of small molecule inhibitor of BMP signaling.

Caroline E. Sanvitale;Georgina Kerr;Apirat Chaikuad;Marie-Christine Ramel

243
Citations
A Mild, One‐Pot Stadler–Ziegler Synthesis of Arylsulfides Facilitated by Photoredox Catalysis in Batch and Continuous‐Flow

Xiao Wang;Gregory D. Cuny;Gregory D. Cuny;Timothy Noël

221
Citations
Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells.

Helena Mistry;Grace Hsieh;Sara J. Buhrlage;Min Huang

198
Citations
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.

Andrea U. Steinbicker;Chetana Sachidanandan;Ashley J. Vonner;Rushdia Z. Yusuf

197
Citations
Development of an ALK2-biased BMP type I receptor kinase inhibitor

Agustin H. Mohedas;Xuechao Xing;Kelli A. Armstrong;Alex N. Bullock

185
Citations
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection

Qiongman Kong;Ling-Chu Chang;Kou Takahashi;Qibing Liu

169
Citations
Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer’s disease

Kou Takahashi;Qiongman Kong;Yuchen Lin;Nathan Stouffer

165
Citations
Structure-activity relationship study of novel tissue transglutaminase inhibitors

Eric Duval;April Case;Ross L. Stein;Gregory D. Cuny

146
Citations
Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.

Chien-Liang Glenn Lin;Qiongman Kong;Gregory D Cuny;Gregory D Cuny;Marcie A Glicksman

146
Citations
Structure Guided Design of Potent and Selective Ponatinib-Based Hybrid Inhibitors for RIPK1

Malek Najjar;Chalada Suebsuwong;Soumya S. Ray;Roshan J. Thapa

145
Citations
Inhibitor of the Tyrosine Phosphatase STEP Reverses Cognitive Deficits in a Mouse Model of Alzheimer's Disease

Jian Xu;Manavi Chatterjee;Tyler D. Baguley;Jonathan Brouillette

144
Citations